lactic acid has been researched along with Intermittent Claudication in 20 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Intermittent Claudication: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.
Excerpt | Relevance | Reference |
---|---|---|
"The TcPO2 electrode was attached to the dorsum of the foot." | 2.67 | Transcutaneous oxygen pressure measurements in patients with intermittent claudication. ( Celsing, F; Eriksson, M; Rosfors, S, 1994) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 9 (45.00) | 18.7374 |
1990's | 4 (20.00) | 18.2507 |
2000's | 6 (30.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (5.00) | 2.80 |
Authors | Studies |
---|---|
Semporé, WY | 1 |
Hersant, J | 1 |
Ramondou, P | 1 |
Hamel, JF | 1 |
Abraham, P | 1 |
Henni, S | 1 |
Parr, B | 1 |
Noakes, TD | 1 |
Derman, EW | 1 |
Zwierska, I | 1 |
Walker, RD | 1 |
Choksy, SA | 1 |
Male, JS | 1 |
Pockley, AG | 1 |
Saxton, JM | 1 |
Westman, B | 1 |
Johansson, G | 1 |
Söderlund, K | 1 |
Wernerman, J | 1 |
Hammarqvist, F | 1 |
Tuner, SL | 1 |
Easton, C | 1 |
Wilson, J | 1 |
Byrne, DS | 1 |
Rogers, P | 1 |
Kilduff, LP | 1 |
Kingsmore, DB | 1 |
Pitsiladis, YP | 1 |
Maass, U | 4 |
Alexander, K | 3 |
Ruell, PA | 1 |
Imperial, ES | 1 |
Bonar, FJ | 1 |
Thursby, PF | 1 |
Gass, GC | 1 |
Qvarfordt, P | 1 |
Eklöf, B | 2 |
Ohlin, P | 1 |
Plate, G | 1 |
Saltin, B | 1 |
Forconi, S | 1 |
Pieragalli, D | 1 |
Acciavatti, A | 1 |
Del Bigo, C | 1 |
Galigani, C | 1 |
Ralli, L | 1 |
Guerrini, M | 1 |
Di Perri, T | 1 |
Sjöström, M | 1 |
Neglén, P | 1 |
Fridén, J | 1 |
Goller, B | 3 |
Grothe, R | 1 |
Schneider, B | 2 |
Rosfors, S | 1 |
Celsing, F | 1 |
Eriksson, M | 1 |
Chello, M | 1 |
Mastroroberto, P | 1 |
Celi, V | 1 |
Romano, F | 1 |
Marchese, AR | 1 |
Colonna, A | 1 |
Tan, KH | 1 |
Cotterrell, D | 1 |
Sykes, K | 1 |
Sissons, GR | 1 |
de Cossart, L | 1 |
Edwards, PR | 1 |
Coolen, SA | 1 |
Wijnen, MH | 1 |
Reijenga, JC | 1 |
Vader, HL | 1 |
Roumen, RM | 1 |
Huf, FA | 1 |
Rexroth, W | 1 |
Hild, R | 1 |
Grote, R | 2 |
Nehmiz, G | 1 |
Brevetti, G | 1 |
Chiariello, M | 1 |
Ferulano, G | 1 |
Policicchio, A | 1 |
Nevola, E | 1 |
Rossini, A | 1 |
Attisano, T | 1 |
Ambrosio, G | 1 |
Siliprandi, N | 1 |
Angelini, C | 1 |
Walker, PM | 1 |
Harris, KA | 1 |
Tanner, WR | 1 |
Harding, R | 1 |
Romaschin, AD | 1 |
Mickle, DA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | Log Minutes (Mean) |
---|---|
Cilostazol + L-Carnitine | 1.065 |
Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
Intervention | Log Minutes (Mean) |
---|---|
Cilostazol + L-Carnitine | 1.001 |
Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | Log Minutes (Mean) |
---|---|
Cilostazol + L-Carnitine | 0.241 |
Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | Log Minutes (Mean) |
---|---|
Cilostazol + L-Carnitine | 0.267 |
Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
Intervention | Log Minutes (Mean) |
---|---|
Cilostazol + L-Carnitine | 0.166 |
Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
Intervention | score on a scale (Mean) |
---|---|
Cilostazol + L-Carnitine | 13.20 |
Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
Intervention | score on a scale (Mean) |
---|---|
Cilostazol + L-Carnitine | 12.98 |
Cilostazol + Placebo | 10.01 |
5 trials available for lactic acid and Intermittent Claudication
Article | Year |
---|---|
Cardiopulmonary responses to treadmill and cycle ergometry exercise in patients with peripheral vascular disease.
Topics: Adult; Bicycling; Cardiovascular System; Exercise Test; Exercise Tolerance; Heart Rate; Humans; Inte | 2008 |
Transcutaneous oxygen pressure measurements in patients with intermittent claudication.
Topics: Aged; Blood Gas Monitoring, Transcutaneous; Exercise Test; Heart Rate; Humans; Intermittent Claudica | 1994 |
Reduction by indobufen of neutrophil activation in peripheral arterial occlusive disease.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Arterial Occlusive Diseases; Cyclooxygenase Inhibitors; H | 1996 |
A new method for measuring oxidative stress in claudicants during strenuous exercise using free radical derivatives of antipyrine as indicators: a pilot study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Exercise; Female; Free Radicals; Humans; | 2002 |
Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study.
Topics: Carnitine; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Female; Humans; Intermitten | 1988 |
15 other studies available for lactic acid and Intermittent Claudication
Article | Year |
---|---|
Exercise Oximetry Correlates Better With Exercise-Induced Lactate Increase, than Ankle Brachial Index or Walking Time, in Vascular Claudicants.
Topics: Ankle Brachial Index; Blood Gas Monitoring, Transcutaneous; Exercise Test; Humans; Intermittent Clau | 2023 |
Factors predicting walking intolerance in patients with peripheral arterial disease and intermittent claudication.
Topics: Exercise Test; Exercise Tolerance; Follow-Up Studies; Humans; Intermittent Claudication; Lactic Acid | 2008 |
Relative tolerance to upper- and lower-limb aerobic exercise in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Blood Pressure; Exercise Therapy; Exercise Tolerance; Extremities; Female; | 2006 |
Muscle glutathione metabolism during ischemia and reperfusion in patients undergoing aorto-bifemoral bypass surgery.
Topics: Aged; Amino Acids; Anesthesia, General; Energy Metabolism; Female; Glutathione; Humans; Intermittent | 2006 |
Effect of treadmill exercise on blood gases and acid-base balance in patients with intermittent claudication.
Topics: Acid-Base Equilibrium; Adult; Aged; Bicarbonates; Carbon Dioxide; Exercise Test; Female; Hemodynamic | 1983 |
Intermittent claudication. The effect of physical training on walking tolerance and venous lactate concentration.
Topics: Aged; Exercise Test; Exercise Therapy; Female; Humans; Intermittent Claudication; Lactates; Lactic A | 1984 |
Intramuscular pressure, blood flow, and skeletal muscle metabolism in patients with venous claudication.
Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Blood Pressure; Chronic Disease; Female; Humans; Il | 1984 |
Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
Topics: Administration, Oral; Arterial Occlusive Diseases; Blood Viscosity; Female; Humans; Hydrogen-Ion Con | 1984 |
Human skeletal muscle metabolism and morphology after temporary incomplete ischaemia.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Adult; Aged; Constriction; F | 1982 |
[The walking-through phenomenon in arterial occlusive disease].
Topics: Adult; Aged; Arterial Occlusive Diseases; Exercise Test; Exercise Therapy; Glycolysis; Humans; Inter | 1995 |
Exercise training for claudicants: changes in blood flow, cardiorespiratory status, metabolic functions, blood rheology and lipid profile.
Topics: Aged; Blood Flow Velocity; Blood Pressure; Cholesterol, HDL; Energy Metabolism; Exercise Test; Exerc | 2000 |
[Biochemical modifications in stress ischemia of the calf muscles].
Topics: Alanine; Ammonia; Energy Metabolism; Humans; Hypoxanthine; Hypoxanthines; Intermittent Claudication; | 1991 |
Lactate and pyruvate kinetics after treadmill exercise in patients with intermittent claudication.
Topics: Adult; Aged; Exercise Test; Humans; Intermittent Claudication; Kinetics; Lactates; Lactic Acid; Male | 1989 |
[Interval exercise in arterial occlusive disease].
Topics: Energy Metabolism; Exercise Test; Humans; Intermittent Claudication; Lactates; Lactic Acid; Male; Mi | 1989 |
Laboratory evaluation of patients with vascular occlusive disease.
Topics: Adenosine Triphosphate; Adult; Aged; Blood Pressure; Glycogen; Humans; Intermittent Claudication; Is | 1985 |